Please use this identifier to cite or link to this item: https://doi.org/10.3390/v13020300
DC FieldValue
dc.titleThe role of nk cells in ebv infection and ebv-associated npc
dc.contributor.authorPng, Yi Tian
dc.contributor.authorYang, Audrey Zhi Yi
dc.contributor.authorLee, Mei Ying
dc.contributor.authorChua, Magdalene Jahn May
dc.contributor.authorLim, Chwee Ming
dc.date.accessioned2022-10-13T07:55:30Z
dc.date.available2022-10-13T07:55:30Z
dc.date.issued2021-02-15
dc.identifier.citationPng, Yi Tian, Yang, Audrey Zhi Yi, Lee, Mei Ying, Chua, Magdalene Jahn May, Lim, Chwee Ming (2021-02-15). The role of nk cells in ebv infection and ebv-associated npc. Viruses 13 (2) : 300. ScholarBank@NUS Repository. https://doi.org/10.3390/v13020300
dc.identifier.issn1999-4915
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/233241
dc.description.abstractA vast majority of the population worldwide are asymptomatic carriers of Epstein-Barr Virus (EBV). However, some infected individuals eventually develop EBV-related cancers, including Nasopharyngeal Carcinoma (NPC). NPC is one of the most common EBV-associated epithelial cancers, and is highly prevalent in Southern China and Southeast Asia. While NPC is highly sensitive to radiotherapy and chemotherapy, there is a lack of effective and durable treatment among the 15%–30% of patients who subsequently develop recurrent disease. Natural Killer (NK) cells are natural immune lymphocytes that are innately primed against virus-infected cells and nascent aberrant transformed cells. As EBV is found in both virally infected and cancer cells, it is of interest to examine the NK cells’ role in both EBV infection and EBV-associated NPC. Herein, we review the current understanding of how EBV-infected cells are cleared by NK cells, and how EBV can evade NK cell-mediated elimination in the context of type II latency in NPC. Next, we summarize the current literature about NPC and NK cell biology. Finally, we discuss the translational potential of NK cells in NPC. This information will deepen our understanding of host immune interactions with EBV-associated NPC and facilitate development of more effective NK-mediated therapies for NPC treatment. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.subjectEpstein-Barr Virus (EBV)
dc.subjectNasopharyngeal Carcinoma (NPC)
dc.subjectNK cells
dc.typeReview
dc.contributor.departmentDEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
dc.description.doi10.3390/v13020300
dc.description.sourcetitleViruses
dc.description.volume13
dc.description.issue2
dc.description.page300
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_v13020300.pdf1 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons